title: Precision medicine path for prostate cancer.
abstract: Almost 90% of patients with metastatic castration-resistant prostate cancer have a clinically actionable genetic alteration, according to a recently published study. Among these patients, researchers found that 65% had genetic changes that could be targeted by investigational or FDA-approved drugs currently used for other cancers, leading to new individualized treatment strategies.
mesh_terms: D006801:Humans; D008297:Male; D057285:Precision Medicine; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*